Abstract

The oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix (Orgovyx – Myovant Sciences/Pfizer) has been approved by the FDA for treatment of advanced prostate cancer in adults.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Treatment Of Advanced Prostate Cancer
  • Oral Gonadotropin-releasing Hormone
  • Cancer In Adults
  • Advanced Prostate Cancer
  • Gonadotropin-releasing Hormone
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Relugolix: A Review in Advanced Prostate Cancer
  • Targeted Oncology
  • Jan 18, 2023
Relevant
Not Relevant
COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?
  • Journal of Urology
  • Jul 1, 2000
Relevant
Not Relevant
The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials
  • European Urology Oncology
  • Apr 1, 2022
Relevant
Not Relevant
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I
  • Journal of Urology
  • Jan 1, 2021
Relevant
Not Relevant
Relugolix: A novel gonadotropin-releasing hormone antagonist for prostate cancer
  • Journal of Pharmacology and Pharmacotherapeutics
  • Jan 1, 2021
Relevant
Not Relevant
Degarelix acetate for the treatment of prostate cancer.
  • Drugs of Today
  • Oct 1, 2009
Relevant
Not Relevant
SOMATOSTATIN ANALOGUES AND ESTROGENS IN THE TREATMENT OF ANDROGEN ABLATION REFRACTORY PROSTATE ADENOCARCINOMA
  • Journal of Urology
  • Nov 1, 2004
Relevant
Not Relevant
Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
  • Therapeutic Advances in Medical Oncology
  • Jan 1, 2021
Relevant
Not Relevant
Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
  • JACC. CardioOncology
  • Mar 1, 2020
Relevant
Not Relevant
Cancer treatment: at what cost?
  • Nursing and Residential Care
  • Mar 2, 2015
Relevant
Not Relevant
Relugolix is the first and currently only Orally-Administered GnRH Receptor Antagonist Approved for the treatment of Prostate Cancer: A Review
  • Asian Journal of Pharmaceutical Research
  • Nov 27, 2021
Relevant
Not Relevant
A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
  • Journal of Urology
  • Nov 1, 2008
Relevant
Not Relevant
Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
  • Drug design, development and therapy
  • Aug 1, 2023
Relevant
Not Relevant
Advanced Prostate Cancer
  • American Journal of Cancer
  • Jan 1, 2002
Relevant
Not Relevant
Receptor Gene Messenger RNA Expression in Metastatic Lesions of Prostate Cancer
  • Journal of Urology
  • Sep 1, 2002
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant